Genzyme, AGTC Announce Gene Therapy Collaboration

and (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving gene therapy.Through the collaboration, Genzyme gains access to AGTC’s extensive expertise using Adeno-Associated Virus (AAV) vectors to deliver genes to patients, including access to AGTC’s novel high-yield manufacturing capabilities for AAV vectors.

These vectors may have therapeutic advantages in several disease areas where Genzyme has active preclinical development programs, including lysosomal storage disorders, cardiovascular disease, central nervous system disorders, immune-mediated disorders, and others.

Genzyme brings to the collaboration more than a decade of experience with gene therapy, involving multiple clinical trials in cardiovascular disease, oncology, and cystic fibrosis.

Financial terms were not disclosed.

“We are delighted to collaborate with an established biotechnology leader like Genzyme, which has contributed heavily to many advances in our understanding of gene therapy,” said Sue Washer, CEO of AGTC. “This agreement is an important validation of AGTC’s technology, and will position us to build on our early work in a number of therapeutic areas and enable us to bring products to market more efficiently.”

“Our work with AGTC will bring Genzyme an impressive technology platform, which includes a scalable, highly productive manufacturing capability with the potential to support future clinical trials and product development,” said Sam Wadsworth, vice president, Translational Research at Genzyme.

AGTC has licensed a significant portion of its intellectual property from the University of Florida where researchers originated this ground-breaking work in gene therapy.

AGTC is developing novel therapeutics for patients with unmet medical needs utilizing the non-pathogenic adeno-associated virus.

AGTC’s first product candidate is a treatment for Alpha One Antitrypsin Deficiency, an inherited form of emphysema; Phase I trials are underway with a potential product launch in early 2009.

AGTC’s investors include Interwest Partners (Menlo Park, California), Intersouth Partners (Durham, North Carolina), MedImmune Ventures (Gaithersburg, Maryland) and Skyline Ventures (Palo Alto, California). The company is located in Gainesville, Florida in the University of Florida’s business development park.

Best Steroids Online

dragon-pharmaceutical
A one-stop resource for ordering Dragon Pharma samples: Cut Mix 150 – 24 hours a day, 7 days a week.

Dragon Pharma Labs Overseas

Winstrol Tabs

Synthetic Anabolic Steroidal Agent
Basic Component: Stanozolol
Producer: Dragon Pharmaceuticals
Package: 1 X 100 pastilles (50 mg/tab)

Enantat 250 - Cheap Price

Administration: Injection
Base Component: Testosterone Enanthate
Produced by: Dragon Pharmaceuticals
Unit: 20 x 10 mL vial (250 mg/mL)
Price: 20 x $30.00

Primobolan 100 - Cheap Price

Administration: Injection
Prime Substance: Methenolone Enanthate
Manufacturer: Dragon Pharma LLC
Pack: 20 x 10 mL vial (100 mg/mL)
Price: 20 x $65.00

Propionat 100 - Discount Price

Administration: Injection
Principal Ingredient: Testosterone Propionate
Made by: Dragon Pharma Labs
Amount: 30 x 10 mL vial (100 mg/mL)
Price: 30 x $20.00

Clenbuterol

Beta-2 Agonist, Bronchodilator
Principal Constituent: Clenbuterol Hydrochloride
Branded by: Dragon Pharmaceuticals
Pack: 1 X 100 tabs (40 mcg/pastille)

Oxymetholon

Synthetic Anabolic Steroidal Agent
Main Ingredient: Oxymetholone
Branded by: Dragon Pharmaceutical
Unit: 1 X 100 pastilles (50 mg/pill)

Clenbuterol - Bulk Price

Administration: Oral
Basal Chemical Name: Clenbuterol Hydrochloride
Produced by: Dragon Pharma
Unit: 10 x 100 tablets (40 mcg/tab)
Price: 10 x $25.00

Dianabol

Natural Anabolic Steroidal Agent
Prime Chemical Name: Methandrostenolone
Made by: Dragon Pharma LLC
Unit: 1 X 100 pills (20 mg/pastille)

TriTren 150 - Cheap Price

Administration: Injection
Principal Substance: Tri Trenbolone
Producer: Dragon Pharmaceuticals
Amount: 20 x 10 mL vial (150 mg/mL)
Price: 20 x $65.00

1-Test Cyp 200

Injectable Steroid for Muscle Growth
Basal Ingredient: Dihydroboldenone Cypionate
Produced by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (200 mg/mL)

EQ 300 [10 Vials]

Injectable Steroid for Muscle Growth
Base Ingredient: Boldenone Undecylenate
Produced by: Dragon Pharma Labs
10 Vials [10 mL per Vial (300 mg/ml)]
Price: 10 x $42.00 = $420.00 in Total

EQ 300

Injectable Steroid for Muscle Growth
Base Constituent: Boldenone Undecylenate
Produced by: Dragon Pharmaceuticals
10 mL Sterile Multi-dose Vial (300 mg/mL)